138%. The increased likelihood of cancer deaths among people taking the new FDA-approved blood test every three years, as recommended, compared to those who undergo colonoscopy once a decade, according to a new study from Stanford Medicine.
83%. The percentage of colorectal tumors detected by the blood test in a clinical trial involving 8,000 patients.
17%. The percentage of patients who paid nothing out-of-pocket for bowel preparation for screening colonoscopies, according to a study led by Eric Shah, MD, at Ann Arbor-based University of Michigan. Many leaders are concerned about how that could affect screening volumes.
36%. The percentage of patients in the same study who had no out-of-pocket costs for prescription bowel preps. For Medicare Part D, only 25% of high-volume preps were free.
15%. The share of the Medicare-approved amount that patients may pay for physician services if a screening colonoscopy becomes diagnostic.
2.8%. The reduction in the physician fee conversion factor by CMS in its 2025 fee schedule. Ten physicians joined Becker’s to discuss the long-term dangers of this reduction.
29%. The decline in Medicare physician payment since 2001, when adjusted for inflation, according to the American Medical Association.
$43.2 billion. The total cost of U.S. cancer screening in 2021. Screening colonoscopies account for $23.7 billion, or 55% of this total.
1,630. The projected national shortage of gastroenterologists by 2025.
8%. The projected growth rate of colon cancer among men in the U.S. in 2024. The expected growth rate among women is 7%.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
